Alembic Indian plant hit with US FDA Form 483 and four observations

By Dan Stanton contact

- Last updated on GMT

Image: iStock/CharlieAJA
Image: iStock/CharlieAJA

Related tags: Food and drug administration

The US FDA has hit an Indian formulation facility run by Alembic Pharmaceuticals with a Form 483 with four observations.

The facility in Panelav, Halol, was inspected by the US Food and Drug Administration (FDA) between 21 and 25 March and in a letter filed with the Bombay Stock Exchange yesterday, Alembic said it received a Form 483.

“The Company had received four observations which are being addressed by our regulatory and quality team,”​ company secretary Ajay Kumar Desai wrote

“We wish to inform you that to the best of our knowledge and understanding the above events or informations [sic] may not have any bearing on the operations / performance of the Company.”

The facility is one of four FDA-approved manufacturing facilities owned by Alembic, but the only one that makes finished formulations for US export, rather than active pharmaceutical ingredients (APIs).

According to the firm’s annual report​, the site was last inspected by the FDA in fiscal year 2014-15 resulting in a “Zero 483.”

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars